Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Lung Neoplasms 12Ovarian Neoplasms 8Carcinoma, Non-Small-Cell Lung 7Fallopian Tube Neoplasms 6Colorectal Neoplasms 5Carcinoma, Hepatocellular 5Urinary Bladder Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Pancreatic Neoplasms 4Carcinoma, Renal Cell 4Neoplasm Metastasis 3Mouth Neoplasms 3Melanoma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Glioblastoma 3Endometrial Neoplasms 3Cholangiocarcinoma 3Thyroid Neoplasms 2Small Cell Lung Carcinoma 2Prostatic Neoplasms 2Oropharyngeal Neoplasms 2Nasopharyngeal Carcinoma 2Mycosis Fungoides 2Multiple Myeloma 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell 2Lymphoid Interstitial Pneumonia 2Laryngeal Neoplasms 2

Interventions

Gemcitabine 15Cisplatin 13durvalumab 10pembrolizumab 9Oxaliplatin 8Magnetic Resonance Spectroscopy 8Specimen Handling 6Leucovorin 6Biopsy 6Fluorouracil 5Paclitaxel 4Folfox protocol 4Taxes 3Radiation 3Nivolumab 3Irinotecan 3Immunoglobulin G 3Disulfides 3tislelizumab 2pemigatinib 2olaparib 2futibatinib 2fludarabine 2dehydroftorafur 2Platinum 2Liver Transplantation 2Fluorodeoxyglucose F18 2Floxuridine 2Dexamethasone 2Carboplatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Cholangiocarcinoma × Disulfides × 90 days × Clear all
NCT07619313 2026-06-04

AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer

Jonsson Comprehensive Cancer Center

Phase 1 Not yet recruiting
46 enrolled
Gastrointestinal

Pancreatic Neoplasms, Cholangiocarcinoma

NCT06058663 2026-05-13

Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma

Mayo Clinic

Phase 1 Recruiting
16 enrolled
Gastrointestinal

Cholangiocarcinoma

NCT03942328 2026-04-20

Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer

Mayo Clinic

Phase 1/2 Recruiting
85 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡